Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
SOF-SKN's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for SOF-SKN.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| SOF-SKN | Noxopharm | Kinase Inhibitor | Phase 1 | 0 | ||||
| A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 | Bristol-Myers Squibb | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
Phase 4 |
| — |
| — |
| — |
| — |
| — |
| Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus | AstraZeneca | — | Phase 3 | — | — | — | — | — |
| A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | AstraZeneca | — | Phase 3 | — | — | — | — | — |
| Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus | Assistance Publique - Hôpitaux de Paris | — | Phase 3 | — | — | — | — | — |
| A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease | EMD Serono Research & Development Institute, Inc. | — | Phase 3 | — | — | — | — | — |
| A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) | EMD Serono Research & Development Institute, Inc. | — | Phase 3 | — | — | — | — | — |
| A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Biogen | — | Phase 3 | — | — | — | — | — |
| A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Biogen | — | PHASE2/PHASE3 | — | — | — | — | — |
| A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) | Bristol-Myers Squibb | — | Phase 2 | — | — | — | — | — |
| Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus | Innovaderm Research Inc. | — | Phase 2 | — | — | — | — | — |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus | Ventus Therapeutics U.S., Inc. | — | Phase 2 | — | — | — | — | — |
| Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study | Beijing InnoCare Pharma Tech Co., Ltd. | — | Phase 2 | — | — | — | — | — |
| A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) | Immunovant Sciences GmbH | — | Phase 2 | — | — | — | — | — |
| The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | — | Phase 2 | — | — | — | — | — |
| A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants | DualityBio Inc. | — | PHASE1/PHASE2 | — | — | — | — | — |